The mass spec-based assay can detect viral proteins eight days after the onset of symptoms, compared to four to five days with PCR tests, its developers said.
Along with WHO, Mologic, and Leiden University Medical Center, FIND is developing two rapid diagnostic tests to detect circulating anodic antigen in blood or urine.
Researchers at Washington University in Saint Louis will use new funds to confirm preliminary findings on malaria-infected kids in a second location in Africa.
Backed by the UK and Swiss governments, FIND's Diagnostics Use Accelerator will support studies that could lead to improved use of antibiotics, as well as new diagnostics.
Developers claim the immunochromatographic assay has advantages over other tests on the market for diagnosing TB in HIV patients, as well as the conventional approach.
Participants at the Next Generation Dx Summit last week noted that POC testing could prove vital in diagnosing and containing highly infectious diseases.
Researchers have established that two simple tests can determine whether a person meets guidelines to receive antiviral treatment.
The partners will further develop a test to guide clinical care of patients with Plasmodium vivax malaria who may also have G6PD deficiency.
At least one HIV self-test from a competitor could reach the global market this year. In addition, the company is in the midst of a strategic review.